Ubs Group Ag Apellis Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 3,272,194 shares of APLS stock, worth $62.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,272,194

Previous 2,586,739 26.5%

Holding current value

$62.6 Million

Previous $82.5 Million 13.3%

% of portfolio

0.01%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$21.87 - $34.63 $15 Million - $23.7 Million	685,455 Added 26.5%	3,272,194 $71.6 Million
Q4 2024 Feb 14, 2025	BUY	$26.18 - $35.42 $59.5 Million - $80.5 Million	2,272,055 Added 722.01%	2,586,739 $82.5 Million
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $1.22 Million - $1.74 Million	42,287 Added 15.52%	314,684 $9.08 Million
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $6.13 Million - $9.62 Million	161,105 Added 144.76%	272,397 $10.4 Million
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $900,530 - $1.18 Million	16,258 Added 17.11%	111,292 $6.54 Million
Q4 2023 Feb 09, 2024	BUY	$37.14 - $64.82 $3.39 Million - $5.91 Million	91,168 Added 2358.2%	95,034 $5.69 Million
Q3 2023 Nov 09, 2023	SELL	$23.65 - $89.22 $2.19 Million - $8.26 Million	-92,589 Reduced 95.99%	3,866 $147,000
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $606,462 - $737,988	-7,909 Reduced 7.58%	96,455 $8.79 Million
Q1 2023 May 12, 2023	SELL	$46.59 - $66.96 $1.28 Million - $1.84 Million	-27,533 Reduced 20.87%	104,364 $6.88 Million
Q4 2022 Feb 08, 2023	BUY	$43.24 - $61.04 $5.07 Million - $7.16 Million	117,258 Added 801.0%	131,897 $6.82 Million
Q3 2022 Nov 10, 2022	SELL	$44.76 - $69.66 $2.57 Million - $4 Million	-57,484 Reduced 79.7%	14,639 $1 Million
Q2 2022 Aug 10, 2022	SELL	$35.07 - $59.21 $1.49 Million - $2.52 Million	-42,526 Reduced 37.09%	72,123 $3.26 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $186,590 - $284,779	5,262 Added 4.81%	114,649 $5.83 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $2.69 Million - $4.3 Million	-87,495 Reduced 44.44%	109,387 $5.17 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $4.42 Million - $9.83 Million	140,763 Added 250.83%	196,882 $6.49 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $1.82 Million - $2.88 Million	44,425 Added 379.9%	56,119 $3.55 Million
Q1 2021 May 12, 2021	BUY	$40.8 - $57.39 $435,050 - $611,949	10,663 Added 1034.24%	11,694 $502,000
Q4 2020 Feb 11, 2021	BUY	$30.79 - $57.2 $22,723 - $42,213	738 Added 251.88%	1,031 $59,000
Q3 2020 Nov 12, 2020	SELL	$25.89 - $33.65 $65,424 - $85,033	-2,527 Reduced 89.61%	293 $9,000
Q2 2020 Jul 31, 2020	SELL	$24.8 - $38.49 $250,926 - $389,441	-10,118 Reduced 78.2%	2,820 $92,000
Q1 2020 May 01, 2020	SELL	$17.91 - $44.33 $106,260 - $263,009	-5,933 Reduced 31.44%	12,938 $347,000
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $264,780 - $369,014	-11,981 Reduced 38.83%	18,871 $578,000
Q3 2019 Nov 14, 2019	SELL	$24.09 - $32.18 $377,586 - $504,389	-15,674 Reduced 33.69%	30,852 $743,000
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $669,150 - $942,014	37,175 Added 397.55%	46,526 $1.18 Million
Q1 2019 May 14, 2019	SELL	$12.81 - $19.82 $702,346 - $1.09 Million	-54,828 Reduced 85.43%	9,351 $182,000
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $437,534 - $713,711	38,146 Added 146.53%	64,179 $847,000
Q3 2018 Nov 14, 2018	BUY	$16.57 - $21.03 $323,844 - $411,010	19,544 Added 301.19%	26,033 $463,000
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $25,479 - $38,940	1,298 Added 25.0%	6,489 $143,000
Q1 2018 May 15, 2018	BUY	$14.01 - $26.02 $18,044 - $33,513	1,288 Added 33.0%	5,191 $115,000
Q4 2017 Feb 14, 2018	BUY	$12.71 - $21.7 $49,607 - $84,695	3,903	3,903 $85,000

Others Institutions Holding APLS

# of Institutions

295

Shares Held

124M

Call Options Held

921K

Put Options Held

761K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.1B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account